Duloxetine Capsule, Delayed Release
Product Images NDC 70518-3287

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-3287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Duloxetine 30 mg delayed-release capsules, quantity 60. The label shows the product name, dosage form, strength, and quantity. It includes the NDC number 70518-3287-00, manufacturing details for Ajanta Pharma Ltd., and repackaging information by RemedyRepack Inc. Warnings and storage directions are partially visible.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier survival curve comparing time from randomization to relapse in days for patients treated with Duloxetine versus placebo. The y-axis shows the proportion of patients with relapse, and the x-axis shows the time in days. Duloxetine shows a lower proportion of patients with relapse over time compared to placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows the percent improvement in pain, with data points connected by lines for each treatment group.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph titled to show the proportion of patients with relapse over time from randomization in days. It compares two treatments, Duloxetine and placebo, showing Duloxetine with a lower relapse proportion curve than placebo across approximately 0 to 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved ranging from 0 to 70%.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg administered twice daily (BID), once daily (QD), and placebo, illustrating that Duloxetine (both dosing regimens) resulted in higher patient improvement percentages than placebo across various levels of pain improvement.*

FDA Label Image

Figure5 (Duloxetine Fig5)

Line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Three lines compare Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends of patient improvement across varying percentages of pain reduction.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine at different doses (120 mg, 60 mg, and 20 mg once daily) with placebo. The y-axis shows the percentage of patients improved, ranging from 0 to 100%, and the x-axis represents percent improvement in pain from baseline, from greater than 0 to 100 percent.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The y-axis shows percentage of patients improved from 0% to 100%, and the x-axis shows percent improvement in pain from baseline ranging from >0% to 100%. Duloxetine consistently shows higher patient improvement percentages than placebo across the measured values.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline (BOCF) ranging from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two lines represent placebo and Duloxetine, with Duloxetine generally showing higher improvement percentages across the pain improvement spectrum.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of Duloxetine hydrochloride, showing the molecular arrangement including a thiophene ring and a naphthyl group linked to an amine hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.